Technical Analysis for URGN - UroGen Pharma Ltd.

Grade Last Price % Change Price Change
grade C 43.26 -3.97% -1.79
URGN closed down 3.97 percent on Wednesday, January 17, 2018, on 1.26 times normal volume.
0 Watchers
Track This Stock
Watchlist Portfolio

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Strong N/A Up Down
See historical URGN trend table...

Date Alert Name Type % Chg
Jan 17 Wide Bands Range Expansion 0.00%
Jan 16 New 52 Week Closing High Bullish -3.97%
Jan 16 Wide Bands Range Expansion -3.97%
Jan 16 Overbought Stochastic Strength -3.97%
Jan 16 Up 3 Days in a Row Strength -3.97%
Jan 16 Up 4 Days in a Row Strength -3.97%
Jan 16 Up 5 Days in a Row Strength -3.97%
Jan 12 Doji - Bearish? Reversal -2.04%
Jan 12 Outside Day Range Expansion -2.04%
Jan 12 Wide Bands Range Expansion -2.04%

Older signals for URGN ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
UroGen Pharma Ltd. (UroGen) is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC). Its other clinical-stage drug candidate includes Vesimune and BotuGel. Vesimune is a formulation of the toll-like receptor7 (TLR7) agonist Imiquimod for local intravesical delivery for the treatment of Carcinoma In-Situ. BotuGel is an intravesical sustained release formulation of botulinum toxin for Overactive Bladder (OAB) and Interstitial Cystitis (IC). UroGen has developed two platform technologies: RTGel and Immunotherapy.
Is URGN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 0 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 46.68
52 Week Low 13.01
Average Volume 135,880
200-Day Moving Average 0.0
50-Day Moving Average 40.1104
20-Day Moving Average 41.0785
10-Day Moving Average 43.811
Average True Range 2.2678
ADX 38.21
+DI 28.54
-DI 11.21
Chandelier Exit (Long, 3 ATRs ) 39.8766
Chandelier Exit (Short, 3 ATRs ) 43.4634
Upper Bollinger Band 46.7039
Lower Bollinger Band 35.4531
Percent B (%b) 0.69
BandWidth 27.388537
MACD Line 1.5984
MACD Signal Line 1.3271
MACD Histogram 0.2713
Fundamentals Value
Market Cap 562.78 Million
Num Shares 13 Million
EPS -1.67
Price-to-Earnings (P/E) Ratio -25.90
Price-to-Sales 20.42
Price-to-Book 4.84
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 45.89
Resistance 3 (R3) 45.92 45.09 45.45
Resistance 2 (R2) 45.09 44.42 45.07 45.30
Resistance 1 (R1) 44.17 44.01 43.76 44.14 45.16
Pivot Point 43.34 43.34 43.13 43.32 43.34
Support 1 (S1) 42.42 42.67 42.01 42.39 41.36
Support 2 (S2) 41.59 42.26 41.57 41.22
Support 3 (S3) 40.67 41.59 41.07
Support 4 (S4) 40.64